CardioNXT develops medical technologies to improve understanding of complex cardiac arrhythmias such as atrial fibrillation and to accurately deliver targeted therapy to ectopic source areas within the heart. Its systems are designed to fit into catheter ablation procedural workflow and to reduce the cost of procedures. The company is based in Westminster, Colorado. CardioNXT secured additional equity funding to support its product development. The new financing will be used to continue development of its device. No operating metrics were disclosed in the article. CardioNXT, led by co-founder and CEO Jerome Edwards, has built a platform of products to enable better understanding of complex cardiac arrhythmias such as atrial fibrillation and to deliver targeted therapy to affected areas within the heart. The company’s products are also designed to reduce the cost of cardiac catheter ablation procedures. CardioNXT secured an additional $1.5M in equity funding to support its development and regulatory efforts. Backers included Solas BioVentures and unnamed existing investors. The company intends to use the funds to advance and obtain regulatory approval for its products in targeted markets within nine months.

Total raised

$4M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2017